FDA Cleared TMS Systems and Specifications

Overview

This is the posttest for the enduring video session, FDA Cleared TMS Systems and Specifications, which was recorded during the 2020 Hands-On TMS Symposium, TMS Bootcamp held in San Francisco, CA in October and November 2020. 

Click here to return to the TMS Health Education site

The TMS Bootcamp modules are for internal provider training purposes only. 

PPP ID: TM20045WC7CJ

 

Target Audience

Employees and colleagues of Mindful Health Solutions who participated in the TMS Bootcamp modules on their TMS Health Education internal website. The TMS Bootcamp modules are for internal provider training purposes only. 

Learning Objectives

After studying this activity, you should be able to:

  • Identify patients who would be appropriate candidates for treatment with TMS
  • Incorporate TMS in your clinical strategies for depression or other psychiatric disorders as appropriate
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
10/17/2020
Activity expires: 
10/31/2022
Cost:
$0.00

CME Background

Brought to you through the joint providership of the CME Institute of Physicians Postgraduate Press, Inc., and TMS Health Solutions.

In-kind support for the live webinar was provided by MagVenture and Neuronetics.

Participants may receive credit by participating in the TMS Bootcamp module provided by Mindful Health Solutions, scoring 70% or higher on the posttest, and completing the evaluation.

CME Objective

After studying this article, you should be able to:

  • Identify patients who would be appropriate candidates for treatment with TMS
  • Incorporate TMS in your clinical strategies for depression or other psychiatric disorders as appropriate

Statement of Need and Purpose

Major depressive disorder (MDD) is not only a leading cause of disability itself, but also increases patients’ risks for comorbid medical conditions. Although effective depression treatments exist, up to 30% of patients do not respond to standard treatments. The TMS system is an FDA-approved treatment for use in adults with treatment-resistant MDD. While TMS is increasingly available, clinicians are unsure about how to use this therapy; thus, it goes underused. Health care providers require education about TMS therapy, how to identify patients who could benefit from it, and how to manage patients during and after an acute treatment course. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on TMS.

Release, Expiration, and Review Dates

This educational activity was published in October 2020 and is eligible for AMA PRA Category 1 Credit™ through October 31, 2022. The latest review of this material was October 2020.

Disclosure of Off-Label Usage

In this meeting, uses of treatments that are not approved by the US Food and Drug Administration may be discussed; please check labeling before prescribing.

Review Process

The faculty members agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair.

Acknowledgment

This CME activity was derived from planning discussions with the faculty, and has been provided in-kind support from MagVenture and Neuronetics. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider, the joint sponsor, or the commercial supporters.
 

Faculty Affiliation


Ian Cook, MD
Los Angeles TMS Institute


 

Financial Disclosure

The faculty for this CME activity, the CME Institute staff, and the TMS Health Solutions staff were asked to complete a statement regarding all relevant personal and financial relationships between themselves or their spouse/partner and any commercial interest. The Accreditation Council for Continuing Medical Education (ACCME) defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff or TMS Health Solutions staff reported any relevant personal financial relationships. Faculty financial disclosure is as follows:

Dr Cook is an employee of Los Angeles TMS Institute; HeartCloud, Inc.; BrainCloud Corp; and NeuroSigma; has received grant/research support from NeuroSigma; and is a stock shareholder of HeartCloud, BrainCloud, and NeuroSigma.

The chair for this CME series, Dr Karl Lanocha, has no personal affiliations or financial relationships with any commercial interest to disclose relative to the activity.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this activity.

Register for free on our site to participate in this and many free CME courses.